UK Markets closed

Zymeworks Inc. (ZYME)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
5.54-0.04 (-0.72%)
As of 12:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.58
Open5.50
Bid5.58 x 900
Ask5.59 x 900
Day's range5.41 - 5.61
52-week range4.11 - 29.62
Volume203,022
Avg. volume758,257
Market cap257.909M
Beta (5Y monthly)1.12
PE ratio (TTM)N/A
EPS (TTM)-3.58
Earnings date01 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.45
  • Zacks

    Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?

    Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • Business Wire

    Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile

    VANCOUVER, British Columbia & SEATTLE, September 26, 2022--Zymeworks Inc. ("Zymeworks" or the "Company") (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that a second independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended shareholders vote FOR the Company’s plan to become a Delaware corporation (the "Redomicile"). ISS’ positive recommendation follows Glass, Lewis & Co.’s ("Glass

  • Business Wire

    Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile

    VANCOUVER, British Columbia & SEATTLE, September 16, 2022--Zymeworks Inc. ("Zymeworks" or the "Company") (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") has recommended that Zymeworks shareholders vote FOR the Company’s plan to become a Delaware corporation (the "Redomicile").